Close
Oncogene
Tumor Supressor Gene
t(11;22)(q24;q11)
EWSR1-FLI1
t(X;18)(p11;q11)
SYT-SSX
t(12;16)(q13;p11)
TLS-DDIT3
t(9;22)(q34;q11)
BCR-ABL
t(15;17)(q22;q21)
PML-RARA
t(11;14)(q13;q32)
IGH-CCND1
t(14;18)(q32;q21)
IGH-BCL2
KRAS
KIT
BRAF
IgH and T-cell receptor clonality testing
t(4;11)
AF4-MLL
t(8;21)
AML1-ETO
t(12;21)
TEL-AML1
BCR-ABL testing
TP53
NPM
4 bp insertion
ABL
Multiple point mutations
FLT3
Tandem duplications, D835 point mutations
Wilms Tumor
Retinoblastoma
Hepatoblastoma
Neuroblastoma
Choroid Plexus Carcinoma
Adrenocorticocarcinoma
Optic Gliomas
Juvenile Myelomonocytic Leukemia
Atypical Teratoid Rhabdoid Tumor
Cancer Risk in Beckwith-Wiedeman Syndrome
Dennys-Drash Syndrome
Trisomy 21 and Leukemia
Transient Myeloproliferative Disorder
Acute Megakaryocytic Leukemia (AMKL)
Rhabdoid Tumor Predisposition Syndrome
Familial Pleuropulmonaryblastoma Tumor Predisposition
RET
MET
HRAS
ALK
Familial and Hereditary Pancreatic Cancer
Cowden Syndrome
Peutz-Jeghers Syndrome
Peutz-Jeghers Syndrome Management
Juvenile Polyposis Coli
Von Hippel Lindau Syndrome
Hereditary Leiomyomatosis and Renal Cell Cancer
Hereditary Diffuse Gastric Cancer
Multiple Endocrine Neoplasia 1
Multiple Endocrine Neoplasia 2
Pheochromocytoma and Paraganglioma Genes
Li-Fraumeni Syndrome
Li Fraumeni Syndrome Management
Gorlin Syndrome
Hereditary Paraganglioma Syndromes
Base excision repair
Nucleotide excision repair
Post-replication repair
Nijmegen breakage syndrome
Bloom syndrome
BRCA1/2
Mismatch repair
Ataxia Telangiectasia
Alveolar rhabdomyosarcoma
Irinotecan
Herceptin
(trastuzumab)
Imatinib mesylate
(Gleevec)
EGFR Non-Small Cell Lung Cancer
Multiple Myeloma
Variable region
Joining region
Constant region
Diversity Region
Philadelphia Chromosome
Burkitt Lymphoma
Two hit theory
Familial Adenomatous Polyposis
Lynch Syndrome
(Hereditary non-polyposis colorectal cancer)
MYH Polyposis
BRCA1
BRCA2
Dysplastic Nevus Syndrome
Birt-Hogg-Dube Syndrome
Manchester Scoring System
Amsterdam Criteria
MUTYH Associated Polyposis
Bethesda Criteria
Mismatch Repair Deficiency Syndrome
Turcot Syndrome
Dyskeratosis Congenita
Nature of Second Hit
Imatanib
Gail Model
Crizotinib
Everolimus
Familial Isolated Pituitary Adenomas
